Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-2036

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-2036). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Divalproex Sodium 500mg 70518 2036 01)

Divalproex Sodium 500 mg extended-release tablet label for a single tablet. The label shows the product name, strength, dosage form, quantity (1 tablet), and a repackaging notice by RemedyRepack Inc. It includes storage information, manufacturer location (Amneal Pharma, Ahmedabad, India), and a QR code.*

FDA Label Image

Mm3 (Divalproex Sodium 500mg 70518 2036 02)

Divalproex Sodium 500 mg Extended-Release Tablet label by RemedyRepack Inc. The label indicates a quantity of 30 tablets, oral route, RX only. Manufactured by Amneal Pharma in Ahmedabad, India, with NDC 70518-2036-02 and source NDC 65162-0757-50. Storage instructions and repackaging information are also included.*

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium extended-release 500 mg oral tablets packaging label showing a quantity of 100 tablets. The label includes the NDC number 70518-2036-00, manufacturer Amneal Pharma, India, and repackager RemedyRepack Inc. Directions advise storage at 20-25°C with permitted excursions. The label states RX only.*

FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

Chemical structure diagram of Divalproex Sodium, showing the molecular arrangement including sodium ions and hydrocarbon chains.*

FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

A cumulative distribution plot comparing percent reduction in CPS rate between Divalproex Sodium and Placebo groups. The y-axis shows percent reduction in CPS rate ranging from -100% to 100%, while the x-axis represents the percent of patients. The solid line indicates Divalproex Sodium, and the dotted line represents Placebo, with annotations for improvement and worsening on the right side.*

FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

A line graph showing percent reduction in CPS rate versus percent of patients for Divalproex Sodium. The solid line represents high dose, and the dashed line represents low dose Divalproex Sodium. The vertical axis ranges from -100% to 100% reduction, indicating worsening to improvement.*

FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

A bar chart comparing Placebo and Divalproex Sodium Extended Release, showing numerical values approximately 0.6 for Placebo and 1.2 for Divalproex Sodium Extended Release. The chart includes labeling of statistical significance (p=0.006).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.